Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pfister

Showing results (551-560 of 666) with videos related to

Pageof 67
Sort By:
Cancer Cell|July 15, 2020
Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric EpendymomaJohannes Gojo, Bernhard Englinger, Li Jiang, et al.
Neuropathology and Applied Neurobiology|December 24, 2019
Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters (DGONC) - a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14M Y Deng, M Sill, D Sturm, et al.
Nature|January 28, 2016
Active medulloblastoma enhancers reveal subgroup-specific cellular originsCharles Y Lin, Serap Erkek, Yiai Tong, et al.
Cancer Cell|November 5, 2013
Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomasSebastian Bender, Yujie Tang, Anders M Lindroth, et al.
Acta Neuropathologica|July 23, 2017
Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcomePooja Panwalkar, Jonathan Clark, Vijay Ramaswamy, et al.
Neuro-Oncology|April 18, 2025
Molecular signatures define BAP1-altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genesPhilipp Sievers, Sonali Arora, Thomas Hielscher, et al.
Neuro-Oncology|August 3, 2023
Mapping pediatric brain tumors to their origins in the developing cerebellumKonstantin Okonechnikov, Piyush Joshi, Mari Sepp, et al.
The Journal of Molecular Diagnostics : JMD|July 30, 2023
Implementation of DNA Methylation Array Profiling in Pediatric Central Nervous System Tumors: The AIM BRAIN Project: An Australian and New Zealand Children's Haematology/Oncology Group StudyChristine L White, Kathryn M Kinross, Molly K Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2021
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)Amar Gajjar, Giles W Robinson, Kyle S Smith, et al.
The Lancet. Oncology|June 2, 2019
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trialJason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Pageof 67

Showing results (551-560 of 666) with videos related to

Sort By:
Pageof 67
Cancer Cell|July 15, 2020
Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric EpendymomaJohannes Gojo, Bernhard Englinger, Li Jiang, et al.
Neuropathology and Applied Neurobiology|December 24, 2019
Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters (DGONC) - a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14M Y Deng, M Sill, D Sturm, et al.
Nature|January 28, 2016
Active medulloblastoma enhancers reveal subgroup-specific cellular originsCharles Y Lin, Serap Erkek, Yiai Tong, et al.
Cancer Cell|November 5, 2013
Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomasSebastian Bender, Yujie Tang, Anders M Lindroth, et al.
Acta Neuropathologica|July 23, 2017
Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcomePooja Panwalkar, Jonathan Clark, Vijay Ramaswamy, et al.
Neuro-Oncology|April 18, 2025
Molecular signatures define BAP1-altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genesPhilipp Sievers, Sonali Arora, Thomas Hielscher, et al.
Neuro-Oncology|August 3, 2023
Mapping pediatric brain tumors to their origins in the developing cerebellumKonstantin Okonechnikov, Piyush Joshi, Mari Sepp, et al.
The Journal of Molecular Diagnostics : JMD|July 30, 2023
Implementation of DNA Methylation Array Profiling in Pediatric Central Nervous System Tumors: The AIM BRAIN Project: An Australian and New Zealand Children's Haematology/Oncology Group StudyChristine L White, Kathryn M Kinross, Molly K Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2021
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)Amar Gajjar, Giles W Robinson, Kyle S Smith, et al.
The Lancet. Oncology|June 2, 2019
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trialJason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Pageof 67